Major depressive disorder carries a significant burden and a high risk for suicide. The need for more effective, safer, and faster-acting drugs is, therefore, compelling. The present chapter briefly assesses the most promising agents, focusing on non-monoamine-targeting compounds, namely, the glutamate antagonist ketamine and its enantiomer esketamine. A critical overview of the evidence and the pitfalls associated with current antidepressant drug development is likewise provided in the following text.
"Novel Psychopharmacology for Depressive Disorders" / Fornaro, Michele; De Berardis, Domenico; Anastasia, Annalisa; Fusco, Andrea. - 1305:(2021), p. 449-461. [10.1007/978-981-33-6044-0_22]
"Novel Psychopharmacology for Depressive Disorders"
Fornaro, Michele;Anastasia, Annalisa;Fusco, Andrea
2021
Abstract
Major depressive disorder carries a significant burden and a high risk for suicide. The need for more effective, safer, and faster-acting drugs is, therefore, compelling. The present chapter briefly assesses the most promising agents, focusing on non-monoamine-targeting compounds, namely, the glutamate antagonist ketamine and its enantiomer esketamine. A critical overview of the evidence and the pitfalls associated with current antidepressant drug development is likewise provided in the following text.File | Dimensione | Formato | |
---|---|---|---|
Major Depressive Disorder - Rethinking and Understanding Recent Discoveries (2021).pdf
solo utenti autorizzati
Descrizione: Vedi capitolo 22
Tipologia:
Documento in Post-print
Licenza:
Accesso privato/ristretto
Dimensione
9.13 MB
Formato
Adobe PDF
|
9.13 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.